A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension - BaxHTN

Inclusion Criteria

• • Male or female participants must be ≥ 18 years old
• • Mean sitting systolic blood pressure on automated office blood pressure measurement ≥ 140 mmHg and < 170 mmHg at Screening
• • Fulfil at least 1 of the following 2 criteria:
• a) uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from different therapeutic classes (at least one should be a diuretic), at maximum tolerated dose in the judgement of the Investigator
• b) rHTN subpopulation: have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one should be a diuretic), at maximum tolerated dose in the judgement of the Investigator
• • Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening
• • Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening
• • Randomisation Criterion:
• • Sitting systolic blood pressure on attended automated office blood pressure measurement of ≥ 135
• mmHg at baseline